- Home
- PSNL vs CRMD Comparison
PSNL vs CRMD Comparison
Compare PSNL & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- CRMD
- Stock Information
- Founded
- PSNL 2011
- CRMD 2006
- Country
- PSNL United States
- CRMD United States
- Employees
- PSNL N/A
- CRMD N/A
- Industry
- PSNL Medical Specialities
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- CRMD Health Care
- Exchange
- PSNL Nasdaq
- CRMD Nasdaq
- Market Cap
- PSNL 460.7M
- CRMD 464.7M
- IPO Year
- PSNL 2019
- CRMD 2010
- Fundamental
- Price
- PSNL $5.14
- CRMD $11.63
- Analyst Decision
- PSNL Strong Buy
- CRMD Strong Buy
- Analyst Count
- PSNL 5
- CRMD 6
- Target Price
- PSNL $8.00
- CRMD $15.00
- AVG Volume (30 Days)
- PSNL 756.3K
- CRMD 2.3M
- Earning Date
- PSNL 05-06-2025
- CRMD 05-06-2025
- Dividend Yield
- PSNL N/A
- CRMD N/A
- EPS Growth
- PSNL N/A
- CRMD N/A
- EPS
- PSNL N/A
- CRMD 0.28
- Revenue
- PSNL $85,694,000.00
- CRMD $82,553,827.00
- Revenue This Year
- PSNL N/A
- CRMD $207.65
- Revenue Next Year
- PSNL $27.82
- CRMD $50.13
- P/E Ratio
- PSNL N/A
- CRMD $41.90
- Revenue Growth
- PSNL 15.57
- CRMD N/A
- 52 Week Low
- PSNL $1.14
- CRMD $3.61
- 52 Week High
- PSNL $7.20
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- PSNL 71.42
- CRMD 69.76
- Support Level
- PSNL $3.98
- CRMD $11.21
- Resistance Level
- PSNL $5.39
- CRMD $12.31
- Average True Range (ATR)
- PSNL 0.36
- CRMD 0.67
- MACD
- PSNL 0.16
- CRMD 0.32
- Stochastic Oscillator
- PSNL 76.38
- CRMD 82.29
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.